Geron EVP Unloads $10,135 in Stock (GERN)
Geron (NASDAQ:GERN) EVP Melissa Kelly Behrs sold 4,826 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $2.10, for a total value of $10,134.60. Following the completion of the sale, the executive vice president now directly owns 143,015 shares of the company’s stock, valued at approximately $300,332. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Geron (NASDAQ:GERN) traded down 1.89% on Friday, hitting $2.08. The stock had a trading volume of 2,891,681 shares. Geron has a 52-week low of $1.06 and a 52-week high of $7.79. The stock’s 50-day moving average is $1.94 and its 200-day moving average is $3.76. The company’s market cap is $326.4 million.
Geron (NASDAQ:GERN) last released its earnings data on Thursday, May 1st. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.35 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was down 38.0% on a year-over-year basis. Analysts expect that Geron will post $-0.25 EPS for the current fiscal year.
A number of analysts have recently weighed in on GERN shares. Analysts at Zacks reiterated a “neutral” rating on shares of Geron in a research note on Tuesday. They now have a $2.25 price target on the stock. Finally, analysts at Wells Fargo & Co. reiterated a “positive” rating on shares of Geron in a research note on Thursday, March 13th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Geron has a consensus rating of “Hold” and a consensus target price of $2.13.
Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.